carnitine has been researched along with Kidney Failure in 10 studies
Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of our work was to test the influence of L-carnitine supplementation on secondary hyperparathyroidism and bone metabolism in hemodialyzed patients in a randomized study." | 7.74 | Effect of L-carnitine supplementation on secondary hyperparathyroidism and bone metabolism in hemodialyzed patients. ( Cibulka, R; Pikner, R; Racek, J; Rajdl, D; Siroka, R; Studenovska, M; Trefil, L; Vesela, E, 2007) |
| "Carnitine plays a crucial role in the metabolism of fatty acids as well as energy production." | 5.72 | Evaluation of the relationship between serum carnitine levels and intradialytic complications in children with kidney failure. ( Abbasi, A; Askarian, F; Bakhtiari Koohsorkhi, M; Bazargani, B; Fahimi, D; Moghtaderi, M; Mojtahedi, SY; Samimi, M, 2022) |
| "We explored the efficacy of intravenous therapy with propionyl L-carnitine in patients with both peripheral arterial disease (PAD) and chronic renal insufficiency requiring haemodialysis." | 5.12 | A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl L-carnitine in patients with peripheral arterial disease requiring haemodialysis. ( Celotta, G; Di Pino, L; Fallico, R; Fatuzzo, P; Ferrante, M; Massimiliano, A; Neri, S; Oliveri Conti, G; Pennisi, G; Rapisarda, F; Signorelli, SS, 2006) |
| "The aim of our work was to test the influence of L-carnitine supplementation on secondary hyperparathyroidism and bone metabolism in hemodialyzed patients in a randomized study." | 3.74 | Effect of L-carnitine supplementation on secondary hyperparathyroidism and bone metabolism in hemodialyzed patients. ( Cibulka, R; Pikner, R; Racek, J; Rajdl, D; Siroka, R; Studenovska, M; Trefil, L; Vesela, E, 2007) |
| "Carnitine is an ammo acid derivative found in high energy demanding tissues (skeletal muscles, myocardium, the liver and the suprarenal glands)." | 2.42 | Carnitine metabolism and deficit--when supplementation is necessary? ( Evangeliou, A; Vlassopoulos, D, 2003) |
| "Carnitine plays a crucial role in the metabolism of fatty acids as well as energy production." | 1.72 | Evaluation of the relationship between serum carnitine levels and intradialytic complications in children with kidney failure. ( Abbasi, A; Askarian, F; Bakhtiari Koohsorkhi, M; Bazargani, B; Fahimi, D; Moghtaderi, M; Mojtahedi, SY; Samimi, M, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bazargani, B | 1 |
| Mojtahedi, SY | 1 |
| Fahimi, D | 1 |
| Askarian, F | 1 |
| Moghtaderi, M | 1 |
| Abbasi, A | 1 |
| Samimi, M | 1 |
| Bakhtiari Koohsorkhi, M | 1 |
| Huang, H | 1 |
| Song, L | 1 |
| Zhang, H | 2 |
| Zhang, J | 1 |
| Zhao, W | 1 |
| Hennermann, JB | 1 |
| Roloff, S | 1 |
| Gellermann, J | 1 |
| Grüters, A | 1 |
| Klein, J | 1 |
| Evangeliou, A | 1 |
| Vlassopoulos, D | 1 |
| Signorelli, SS | 1 |
| Fatuzzo, P | 1 |
| Rapisarda, F | 1 |
| Neri, S | 1 |
| Ferrante, M | 1 |
| Oliveri Conti, G | 1 |
| Fallico, R | 1 |
| Di Pino, L | 1 |
| Pennisi, G | 1 |
| Celotta, G | 1 |
| Massimiliano, A | 1 |
| Cibulka, R | 1 |
| Racek, J | 1 |
| Pikner, R | 1 |
| Rajdl, D | 1 |
| Trefil, L | 1 |
| Vesela, E | 1 |
| Studenovska, M | 1 |
| Siroka, R | 1 |
| Wolk, R | 1 |
| Kalinowski, M | 1 |
| Popławski, A | 1 |
| Mazerska, M | 1 |
| Daniluk, A | 1 |
| Nikolaos, S | 1 |
| George, A | 1 |
| Telemachos, T | 1 |
| Maria, S | 1 |
| Yannis, M | 1 |
| Konstantinos, M | 1 |
| Jacob, C | 1 |
| Belleville, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of Hemodialysis on Plasma Carnitine Levels in Patients With End Stage Renal Disease[NCT05817799] | Phase 2/Phase 3 | 83 participants (Anticipated) | Interventional | 2023-01-01 | Recruiting | ||
| In Vivo Study of Safety, Tolerability and Dosing Effect on SMN mRNA and Protein Levels of Valproic Acid in Patients With Spinal Muscular Atrophy[NCT00374075] | Phase 1 | 42 participants | Interventional | 2003-09-30 | Completed | ||
| Phase I/II Trial of Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy Type I (CARNI-VAL Type I)[NCT00661453] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)[NCT00227266] | Phase 2 | 94 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00661453)
Timeframe: -2 weeks, time 0, 3 months, 6 months
| Intervention | g (Mean) | |||||
|---|---|---|---|---|---|---|
| Lean Mass Baseline | Lean Mass 3 months | Lean Mass 6 months | Fat Mass Baseline | Fat Mass 3 months | Fat Mass 6 months | |
| SMA Type 1 | 4317.15 | 4993.92 | 5133.83 | 3011.37 | 3618.25 | 4316.08 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 2.28 | 2.32 |
| Cohort 1b Sitters Treatment | 2.93 | 2.37 |
| Cohort 2 Standers and Walkers - Treatment | 5.52 | 6.56 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 1.91 | 1.44 |
| Cohort 1b Sitters Treatment | 2.2 | 1.8 |
| Cohort 2 Standers and Walkers - Treatment | 5.3 | 5.85 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 5.46 | 5.28 |
| Cohort 1b Sitters Treatment | 5.45 | 5.26 |
| Cohort 2 Standers and Walkers - Treatment | 14.85 | 16.26 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 3.6 | 3.74 |
| Cohort 1b Sitters Treatment | 4.6 | 3.4 |
| Cohort 2 Standers and Walkers - Treatment | 13.65 | 16.85 |
Comparison of Modified Hammersmith Change from baseline to 6 months. Scores range from 0 to 40. A higher score indicates a better outcome. This scale is used to assess gross motor abilities of non-ambulant children with SMA in multiple research trials as well as in clinical settings. (NCT00227266)
Timeframe: 0 months, 6 months
| Intervention | Score (Mean) | ||
|---|---|---|---|
| Baseline visit (0 weeks) | 6 Month visit (V2) | Change from Baseline | |
| Cohort 1a Sitters Placebo Then Treatment | 20.0 | 20.6 | 0.6 |
| Cohort 1b Sitters Treatment | 16.6 | 16.8 | 0.2 |
"Baseline Modified Hammersmith Extend testing. The baseline test is the score they receive during their screening visits. This scale ranges from 0 to 56. A higher score indicates a better outcome.~This scale is used to assess gross motor abilities of children with SMA in multiple research trials as well as in clinical settings." (NCT00227266)
Timeframe: 1 month prior to enrollment, at enrollment (0 months)
| Intervention | Score (Mean) | |
|---|---|---|
| Modified Hammersmith Extend at S1 (-4 weeks) | Modified Hammersmith Extend at S2 (0 weeks) | |
| Cohort 2 Experimental | 47.0 | 48.3 |
3 reviews available for carnitine and Kidney Failure
| Article | Year |
|---|---|
Influence of L-carnitine supplementation on serum lipid profile in hemodialysis patients: a systematic review and meta-analysis.
Topics: Animals; Carnitine; Dietary Supplements; Humans; Hypolipidemic Agents; Lipids; Randomized Controlled | 2013 |
Carnitine metabolism and deficit--when supplementation is necessary?
Topics: Animals; Carnitine; Diabetes Mellitus; Energy Metabolism; Heart Failure; Humans; Mitochondria, Muscl | 2003 |
Carnitine metabolism and deficit--when supplementation is necessary?
Topics: Animals; Carnitine; Diabetes Mellitus; Energy Metabolism; Heart Failure; Humans; Mitochondria, Muscl | 2003 |
Carnitine metabolism and deficit--when supplementation is necessary?
Topics: Animals; Carnitine; Diabetes Mellitus; Energy Metabolism; Heart Failure; Humans; Mitochondria, Muscl | 2003 |
Carnitine metabolism and deficit--when supplementation is necessary?
Topics: Animals; Carnitine; Diabetes Mellitus; Energy Metabolism; Heart Failure; Humans; Mitochondria, Muscl | 2003 |
Carnitine metabolism and deficit--when supplementation is necessary?
Topics: Animals; Carnitine; Diabetes Mellitus; Energy Metabolism; Heart Failure; Humans; Mitochondria, Muscl | 2003 |
Carnitine metabolism and deficit--when supplementation is necessary?
Topics: Animals; Carnitine; Diabetes Mellitus; Energy Metabolism; Heart Failure; Humans; Mitochondria, Muscl | 2003 |
Carnitine metabolism and deficit--when supplementation is necessary?
Topics: Animals; Carnitine; Diabetes Mellitus; Energy Metabolism; Heart Failure; Humans; Mitochondria, Muscl | 2003 |
Carnitine metabolism and deficit--when supplementation is necessary?
Topics: Animals; Carnitine; Diabetes Mellitus; Energy Metabolism; Heart Failure; Humans; Mitochondria, Muscl | 2003 |
Carnitine metabolism and deficit--when supplementation is necessary?
Topics: Animals; Carnitine; Diabetes Mellitus; Energy Metabolism; Heart Failure; Humans; Mitochondria, Muscl | 2003 |
[L-carnitine: metabolism, functions and value in pathology].
Topics: Adolescent; Adult; Biological Transport, Active; Carnitine; Carnitine Acyltransferases; Child; Child | 1992 |
1 trial available for carnitine and Kidney Failure
| Article | Year |
|---|---|
A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl L-carnitine in patients with peripheral arterial disease requiring haemodialysis.
Topics: Aged; Aldehydes; Carnitine; Double-Blind Method; Humans; Malondialdehyde; Middle Aged; Nitrates; Nit | 2006 |
6 other studies available for carnitine and Kidney Failure
| Article | Year |
|---|---|
Evaluation of the relationship between serum carnitine levels and intradialytic complications in children with kidney failure.
Topics: Adolescent; Cardiomyopathies; Carnitine; Child; Humans; Hyperammonemia; Hypotension; Kidney Failure, | 2022 |
False-positive newborn screening mimicking glutaric aciduria type I in infants with renal insufficiency.
Topics: Amino Acid Metabolism, Inborn Errors; Brain Diseases, Metabolic; Carnitine; Diagnosis, Differential; | 2009 |
Effect of L-carnitine supplementation on secondary hyperparathyroidism and bone metabolism in hemodialyzed patients.
Topics: Aged; Bone and Bones; Bone Density; Calcium; Carnitine; Dietary Supplements; Female; Humans; Hyperpa | 2007 |
Micronutrition in dialysis.
Topics: Carnitine; Humans; Nutritional Physiological Phenomena; Renal Insufficiency; Renal Replacement Thera | 1993 |
[Effects of L-carnitine on erythropoiesis and blood platelet aggregation in patients with chronic renal failure treated with hemodialysis].
Topics: Adult; Carnitine; Chronic Disease; Erythropoiesis; Erythropoietin; Female; Humans; Male; Middle Aged | 1999 |
Effect of L-carnitine supplementation on red blood cells deformability in hemodialysis patients.
Topics: Adult; Aged; Carnitine; Erythrocyte Deformability; Female; Humans; Male; Middle Aged; Renal Dialysis | 2000 |